$130MSeries B, 7 August 2025
Funds will complete a pivotal trial and begin early commercialization.
- Amount
- $130M
- Stage
- Series B
- Announced
- 7 August 2025
- Lead
- Bain Capital Life Sciences
- Other investors
- Norwest Venture Partners, F-Prime Capital, Intuitive Ventures, Lightstone Ventures, Santé Ventures
- Use of funds
- Funds will complete a pivotal trial and begin early commercialization.
- Checked
- Announced by the company
- Sources
- Apreo Health secures $130 Million Series B funding to advance emphysema treatment trial - Medical Economics businesswire.com
Apreo Health secures $130 Million Series B funding to advance emphysema treatment trial medicaleconomics.com
Apreo Health secures $130 Million Series B funding to advance emphysema treatment trial - Medical Economics Medical Economics